VALBY, Denmark, Aug. 29, 2002 (PRIMEZONE) -- As part of placement of financial resources, Carlsberg A/S is planning, among other, to invest in biotech. The latest addition is VersaMatrix A/S, a new biotech company which is owned 100 per cent by Carlsberg and which Carlsberg will finance with an amount of up to DKK 25 mill. Furthermore, Carlsberg has contributed additional capital to Combio A/S, and contributed DKK 10 mill. to DTUInnovation. It has also agreed to invest an amount of up to DKK 75 mill. in Care Capital, an American venture fund managed by Jan Leschly. Carlsberg has established a department which will manage investments in biotech and evaluate the opportunities for further investments in own activities and external biotech companies. Carlsberg intends to redecorate a storage building which will be equipped with laboratories and offices.